Marketing: Page 14
-
Permission granted by Biogen
European regulators say no to Aduhelm, but Biogen is pushing back
The company plans to ask the European Medicines Agency to reexamine its conclusion that "the benefits of Aduhelm do not outweigh its risks."
By Jacob Bell • Dec. 17, 2021 -
Getty Images
J&J's coronavirus vaccine faces new US limits
Days after the FDA strengthened safety warnings for J&J's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred."
By Jonathan Gardner • Updated Dec. 17, 2021 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Humana, Centene sue drugmakers, alleging anticompetitive practices on HIV drugs
The insurers filed suit against Gilead, J&J, Bristol Myers Squibb and Teva, claiming the drugmakers conspired to protect lucrative HIV drugs from competition.
By Rebecca Pifer Parduhn • Dec. 14, 2021 -
AbbVie's blockbuster weighed down by safety concerns for a similar Pfizer drug
Like Pfizer's Xeljanz, the label for AbbVie's Rinvoq has been updated to warn about risks of death and major cardiovascular events like stroke.
By Jacob Bell • Dec. 6, 2021 -
Stockbakery/Shutterstock.com
Sponsored by Veeva CrossixAudience targeting in a changing digital landscape
How will your digital advertising strategy evolve in a future without cookies?
Dec. 6, 2021 -
Permission granted by Biogen
Anticipating Aduhelm's costs, Medicare plans big jump in premiums
While CMS is still weighing whether to authorize wide coverage of Biogen's pricey Alzheimer's drug, administrators are planning to build reserves in case costs skyrocket.
By Jonathan Gardner • Nov. 15, 2021 -
Permission for use granted by IQVIA
Sponsored by IQVIAIQVIA Omnichannel Navigator: A platform for informing smarter marketing decisions
This year, the pharmaceutical industry will spend more on its promotional activities than any year before. It’s estimated that the total U.S. promotional spend for 2021 will be around $30 billion.
By Kathryn Grimshaw • Nov. 8, 2021 -
Permission granted by IQVIA
Sponsored by IQVIAPatients, payers, policy and pressure: Trends to watch in 2021
It has become increasingly difficult to forecast and achieve net sales goals. Pressures were building long before 2020, and the COVID-19 pandemic has only accelerated and amplified the challenges.
Nov. 1, 2021 -
Jon Cherry via Getty Images
CDC panel backs COVID-19 boosters for Moderna, J&J vaccine recipients
Advisers' recommendations followed the FDA's clearance of additional doses for certain people vaccinated with Moderna's and J&J's shots, while also endorsing a mix-and-match approach.
By Jonathan Gardner , Shoshana Dubnow • Updated Oct. 22, 2021 -
Permission granted by Biogen
Biogen's Alzheimer's drug is struggling, and a turnaround might not be coming soon
Sales of Aduhelm during the third quarter totaled only $300,000, falling well below expectations amid controversy over its approval and physician reluctance to prescribe it.
By Jacob Bell • Oct. 20, 2021 -
Sage, Biogen detail plans to get their newer depression drug approved
Following discussions with the FDA, the companies plan to submit zuranolone for approval in major depressive disorder and postpartum depression over the next roughly year and a half.
By Jacob Bell • Oct. 19, 2021 -
Boehringer wins 'interchangeable' status for Humira copy, strengthening competitive threat
The interchangeable approval could help to boost adoption of Boehringer's biosimilar when it launches in mid-2023, a date set via settlement with AbbVie.
By Ned Pagliarulo • Oct. 18, 2021 -
Courtesy of Eli Lilly
Lilly drug cleared by FDA for wider use in breast cancer
Verzenio now has an expanded approval for treatment of a common form of early cancer, although the label granted by FDA places some limits on use.
By Kristin Jensen • Oct. 13, 2021 -
Permission granted by Biohaven Pharmaceutical
Biohaven migraine drug sales again top Wall Street forecasts
The neuroscience-focused biotech continues to win market share in a battle with some of the industry's largest companies.
By Kristin Jensen • Oct. 6, 2021 -
Mark Wilson via Getty Images
Lilly, Novartis, other pharmas could face fines for violating 340B law
The U.S. health department asked its inspector general to review the refusals of six drugmakers to offer discounts to safety net hospitals through community pharmacy partnerships.
By Rebecca Pifer Parduhn • Sept. 24, 2021 -
Kevin C. Cox via Getty Images
CDC recommends Pfizer booster shots for many, overruling advisers on broad use
While agency advisers voted against recommending a third Pfizer vaccine dose for frontline workers, they were overruled by CDC Director Rochelle Walensky, who officially endorsed use in that group.
By Shoshana Dubnow , Ned Pagliarulo • Updated Sept. 24, 2021 -
Takeda wins FDA approval for targeted lung cancer drug
Exkivity follows Johnson & Johnson's Rybrevant on the market for treating lung tumors harboring specific mutations in the EGFR gene. Unlike J&J's drug, however, Takeda's is given orally.
By Kristin Jensen • Sept. 16, 2021 -
Permission granted by University of Maryland School of Medicine
New data from Israel, Pfizer show potent effect from third coronavirus shot
The much-anticipated data arrive ahead of an important FDA advisory meeting to discuss authorization of a booster dose for Pfizer's coronavirus vaccine.
By Jonathan Gardner • Sept. 15, 2021 -
Permission granted by IQVIA
Sponsored by IQVIAOvercoming inertia: Adopting omnichannel marketing for pharma
Pharmaceutical companies are increasingly attracted to the idea of replacing the current multichannel marketing focus with an omnichannel marketing approach. But the industry is struggling to break out of its own silos.
By Andrew Burkus, Principal, Omnichannel Marketing, IQVIA • Sept. 13, 2021 -
Permission granted by Biogen
Biogen offered a window into what's holding up Aduhelm. Investors didn't like what they saw.
At Morgan Stanley’s healthcare conference last week, executives detailed how the launch of their Alzheimer’s drug has been slower than expected, due in large part to lingering questions about trial data and insurance coverage.
By Jacob Bell • Sept. 9, 2021 -
Sean Gallup via Getty Images
Settling lawsuit, AstraZeneca and European Commission agree on coronavirus vaccine delivery
The U.K.-based drugmaker fell behind on its promise to supply 300 million doses by the end of June to countries in the trading bloc. Now, it's set to reach that target by March 2022.
By Jonathan Gardner • Sept. 3, 2021 -
Sarah Silbiger via Getty Images
With safety worries mounting, FDA limits who can take certain immune-regulating drugs
The agency has new rules for who can take Pfizer's Xeljanz, Eli Lilly's Olumiant or AbbVie's Rinvoq after a large study raised concerns about the safety of so-called JAK inhibitors.
By Jacob Bell • Sept. 1, 2021 -
Elizabeth Regan/BioPharma Dive
BioMarin wins European approval to sell drug for dwarfism
The drugmaker is setting the price for Voxzogo high, at an annual price of around $300,000 per patient, although the company expects to make "material discounts" in the coming years.
By Ned Pagliarulo • Aug. 27, 2021 -
Permission granted by UPS
UPS delivers coronavirus vaccines via temperature-controlled drone
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas.
By Matt Leonard • Aug. 25, 2021 -
Courtesy of Eli Lilly
Lilly, preparing Alzheimer's drug plans, forms new neuroscience unit in company restructure
Lilly Bio-Medicines will be split into separate neuroscience and immunology groups, while the Loxo cancer research division will merge with Lilly Oncology.
By Jonathan Gardner • Aug. 17, 2021
Previous
